Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists
NCT06640972 on ClinicalTrials.gov · last registry update 2026-07-02
Finished 4 January 2025, after enrolling 68 people. Primary outcome, as filed: Incremental Postprandial Triglycerides (TG). semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Response Pharmaceuticals
- Sponsor type
- Industry
- Enrollment
- 68
- Started
- 2024-09-27
- Primary completion
- 2025-01-04 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Incremental Postprandial Triglycerides (TG)
Conditions studied
Triglycerides · Weight Gain Trajectory · Cholesterol, Elevated
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.